Scholars Central

ArticlePublished 11 Apr 2023

Dopamine 2 agonists for identification and management of type 2 diabetes

Authors: Beyene Dereje, Aschalew Nardos

Systematic Reviews in Pharmacy

Volume 14 · Issue 4 · Pages 286–295

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Dopamine 2 receptor agonists, Bromocriptine and Cabergoline, were originally introduced for prolactinomas and pituitary tumors but have glucose-lowering effects. This paper studied the significance of their effects on lowering blood glucose level and conducted a comprehensive analysis to identify relevant clinical trials of dopamine 2 agonists on Glycated Hemoglobin (HbA1c) and Fasting Blood Sugar (FBS). Methods: We conducted a study using different databases; PubMed, Google Scholar, Cochrane Library, HINARI, Registers, and Citations until December 31, 2022 using the PRISMA 2020 statement, looking for studies relevant to clinical studies on FBS and HbA1c. Jadad score were used to assess the study quality. The study included studies with full abstracts, predefined garlic doses, clear interventions, and blood glucose measurements. Results: Data were synthesized from 23 clinical studies that recruited 6125 study subjects. The pooled effect analysis of the trials revealed that dopamine 2 agonists improve glycated hemoglobin (HbA1c) (SMD=-1.26; 95% CI (-1.60,-0.93), p<0.00001), and FBS (SMD=-1.84; 95% Confidence Limit (CI) (-2.61,-1.07), p<0.00001). Each drug’s pooled effect analysis indicates bromocriptine significantly improved HbA1c (SMD=-1.25; 95% CI (-1.64,-0.87), p<0.00001) and FBS (SMD=-1.90; 95% CI (-2.79,-1.01), p<0.00001) and similarly, cabergoline significantly improved HbA1c (SMD =-1.29; 95% CI (-1.96, -0.62), p<0.00001) and FBS (SMD=-1.62; 95% CI (-2.82,-0.41), p<0.00001). The data presented above demonstrated that dopamine 2 agonists have a significant ability to lower blood sugar levels in clinical studies Conclusion: The study shows that dopamine 2 agonists have significantly reduced glycated hemoglobin and fasting blood sugar levels without major side effects. Although there are encouraging results, more data is required to determine the best anti-hyperglycemic dose and frequency of daily use, as well as side effects and possible product interactions when using dopamine 2 receptor agonists for their anti-hyperglycemic benefits.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalSystematic Reviews in Pharmacy
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Beyene Dereje”
  • BylineArticles whose byline prints “Aschalew Nardos”